Experimental PharmacologyCognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138
References (526)
Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application
Pharmacol Ther
(2006)- et al.
Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs
NeuroRx
(2006) - et al.
Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour
Neurosci Biobehav Rev
(2007) - et al.
Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia
Biol Psychiatry
(2006) Stress activation of glutamate neurotransmission in the pre-frontal cortex: implications for dopamine-associated psychiatric disorders
Biol Psychiatry
(2002)- et al.
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review
Lancet
(2007) - et al.
Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1)
Neurochem Int
(2007) - et al.
PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia
Schizophr Res
(2008) - et al.
A role for microtubules in mental diseases?
Pathol Biol
(2004) - et al.
Microtubule stabilizer ameliorates synaptic function and behaviour in a mouse model for schizophrenia
Biol Psychiatry
(2006)
Stop knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating
Behav Brain Res
(2005)
Genetic mouse models to schizophrenia: from hypothesis-based to susceptibility gene-based models
Biol Psychiatry
(2006)
Genes and the parsing of cognitive processes
Trends Cogn Sci
(2004)
Schizophrenia susceptibility genes: emergence of positional candidates and future directions
Trends Pharmacol Sci
(2006)
Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons
Int Rev Neurobiol
(2007)
Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis
Genet Med
(2007)
N-demethyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels
Schizophr Res
(2006)
Significant association between the genetic variations in the 5’ end of the NMDA receptor subunit gene GRIN1 and schizophrenia
Biol Psychiatry
(2006)
G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis
Biol Psychiatry
(2006)
Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis
Schizophr Res
(2008)
Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia
Biol Psychiatry
(2007)
CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95
Neuron
(1998)
The neuregulin-1 receptor erbB4 controls gluta-matergic synapse maturation and plasticity
Neuron
(2007)
R4 RGS proteins: regulation of G protein signaling and beyond
Pharmacol Ther
(2007)
The role of phosphatidylinositide 3-kinase-protein-kinase B pathway in schizophrenia
Pharmacol Ther
(2006)
Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia
Am J Hum Genet
(2002)
Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributated to the down-regulation of dysbindin
Biochem Biophys Res Commun
(2006)
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Prog Neuropsychopharmacol Biol Psychiatry
(2003)
Metabotropic glutamate receptor targets for neuropsychiatric disorders
Drug Discov Today: Ther Stategies
(2006)
Cognitive factors in schizophrenia: causes, impact, and treatment
CNS Spectr
(2004)
Baseline neurocognitive deficits in the CATIE schizophrenia trial
Neuropsychopharmacology
(2006)
Schizophrenia: a common disease caused by multiple rare alleles
Br J Psychiatry
(2007)
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Mol Psychiatry
(2007)
Schizophrenia: an integrative approach to modelling a complex disorder
J Psychiatry Neurosci
(2006)
The neurodevelopmental model of schizophrenia: update 2005
Mol Psychiatry
(2005)
Predictors of schizophrenia: a review
Br Med Bull
(2005)
Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring
Am J Psychiatry
(2004)
Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms
Mol Psychiatry
(2001)
Cannabis use and psychiatric and cognitive disorders: the chicken or the egg?
Curr Opin Psychiatry
(2007)
The environment and schizophrenia: the role of cannabis use
Schizophr Bull
(2005)
Cannabis and psychosis: an update on course and biological plausible mechanisms
Curr Opin Psychiatry
(2007)
Behavioural sensitization to daily life stress in psychosis
Psychol Med
(2005)
The genetics of schizophrenia and bipolar disorder: dissecting psychosis
Med Genet
(2005)
How and why genetic linkage has not solved the problem of psychosis: review and hypothesis
Am J Psychiatry
(2007)
Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia
Science
(2008)
The DISC locus in psychiatric illness
Mol Psychiatry
(2008)
DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder
Mol Psychiatry
(2008)
Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness
J Physiol
(2007)
Disrupted-in-schizophrenia-1 (DISC1): a key susceptibility factor for major mental illnesses
Ann N Y Acad Sci
(2006)
Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels
J Neurosci
(2007)
Cited by (47)
Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders
2020, Neuroscience and Biobehavioral ReviewsModeling Schizophrenia in Animals
2017, Animal Models for the Study of Human Disease: Second EditionThe atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets
2016, Behavioural Brain ResearchCitation Excerpt :Patients with schizophrenia suffer from widespread cognitive impairment, which correlates with their functional outcome (e.g., community outcome, daily activities and social problem solving) [1,2]. Recent preclinical studies have shown that the dopamine D3 receptor may be an attractive therapeutic target for treatment of cognitive impairment associated with schizophrenia [3–6]. Whereas the dopamine D3 receptor-preferring agonists (+)-PD-128907 and 7-OH-DPAT disrupt several domains of cognitive function [3,4,7], the dopamine D3 receptor antagonists SB277011, NGB2904, S33138 and S33084 are known to produce procognitive effect in several rodent behavioral tasks [3–5,8,9].
Copyright © 2008 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS. Published by Elsevier Masson SAS All rights reserved.